rais tafamidi sale peak
tafamidi solidifi futur std care rais estimate
present detail result tafamidi ttr cardiomyopathi ttr-cm see
takeaway note overal see tafamidi well posit cm market
increas peak sale forecast higher treat
patient off-set slightli lower estimate price rais po reiter
tanezumab pain remain five data trial readout pfe novel jak
inhibitor monotherapi trial atop dermat readout mid
host confer call two academ cardiologist one ex-u review key
takeaway result data encourag describ result
breakthrough becom new standard care cm us specialist
view tafamidi option cm patient ex-u specialist envis use
nyha class i-ii patient biggest debat interpret cv hospit rate
class patient pbo numer better expect label includ class given
tafamidi safeti high unmet need cm competit read-through us
specialist believ pbo-control studi longer feasibl ttr-cm given
enrol challeng ethic concern ttr knockdown alny/ion pivot cm
studi expect design vs tafamidi /- combo arm imper
show superior silenc combin vs tafamidi monotherapi
reg approv commerci execut pfizer
analyst confer call provid clariti time approv management
expect earli approv cm cite strength data spa agreement fda
market develop est patient preval cm
us management state remain significantli underdiagnos requir signific
market develop management view approv tafamidi catalyst lead
referr us center excel present key
increas diagnosi rate vs current preval price declin
comment price note averag eu/japan price base polyneuropathi
valu proposit outcom data updat model assum us averag
price/pt/year
full definit iqmethod sm measur see page
bofa merril lynch seek busi issuer cover research report
result investor awar firm may conflict interest could
affect object report investor consid report singl
factor make invest decis
refer import disclosur page analyst certif page price object
basis/risk page
net dbt
return capit employ
return equiti
iqmethod sm qualiti earn
net incom cont oper
chang work capit
full definit iqmethod sm measur see page
global biopharmaceut compani
diversifi portfolio product pipelin
candid one largest pharma
compani world measur market
capit revenu compon
jone industri averag compani
commerci oper bifurc two
busi segment innov ih
essenti eh gener
revenu total
view compani current valuat
undemand rel compani forward
ep growth face modest near-
term patent cliff encourag recent
event strengthen market leadership
key innov space offer attract
view sustain dividend
on-going strateg review consum busi
state intent engag post us tax
reform outcom could enhanc sharehold
price object po base blend averag dcf forward price-to-earnings po
impli stock could trade ep current
multipl consensu ep multipl base
regress analysi histor us major pharma forward month price-to-earnings multipl
year forward compound-annual-growth-rate ep believ dcf analysi base reason
assumpt includ modest sale growth cagr
respect reflect loss exclus lyrica viagra collect
account us sale forecast near-term headwind
off-set key growth brand xeljanz ibranc xtandi flat
sale growth follow downward rebas us sale pipelin
overal sale forecast out-year sale dcf assum
wacc tgr
risk sale downsid us sale continu declin and/or competit
take meaning market share ibranc could lead downsid estim
po inabl grow busi line forecast hold opex
spend flat level throughout forecast period transact
perceiv valu destruct dcf analysi reflect valu futur
 transact core element strategi
jason gerberri herebi certifi view express research report
accur reflect person view subject secur issuer also
certifi part compens directli indirectli relat
specif recommend view express research report
us major specialti pharmaceut coverag cluster
compani
qualiti earn
iqmethod smi set bofa merril lynch standard measur serv maintain global consist three broad head busi perform qualiti earn valid key featur
iqmethod consist structur detail transpar methodolog guidelin maxim effect compar valuat process identifi common pitfal
iqdatabas real-tim global research databas sourc directli equiti analyst earn model includ forecast well histor data incom statement balanc sheet cash
flow statement compani cover bofa merril lynch
iqprofil sm iqmethod sm servic mark america corpor iqdatabas regist servic mark america corpor
invest opinion system contain end report head fundament equiti opinion dark grey shade indic secur restrict opinion suspend medium grey
shade indic secur review opinion withdrawn grey shade indic secur cover chart current juli later date indic
equiti invest rate distribut health group jun
equiti invest rate distribut global group jun
issuer invest bank client bofa merril lynch one affili within past month purpos invest rate distribut coverag univers includ stock
stock rate neutral includ hold stock rate under-perform includ sell
price fluctuat medium high invest rate reflect analyst assess stock absolut total return potenti ii
attract invest rel stock within coverag cluster defin three invest rate buy stock expect total
return least attract stock coverag cluster neutral stock expect remain flat increas valu less attract
buy rate stock under-perform stock least attract stock coverag cluster analyst assign invest rate consid among thing
month total return expect stock firm guidelin rate dispers shown tabl current price object stock
referenc better understand total return expect given time price object reflect analyst view potenti price appreci depreci
fundament equiti opinion opinion includ volatil risk rate invest rate incom rate volatil risk rate indic potenti
total return expect within period date initi rate
